Table 1

Patient characteristics of the study population

Patient		Age (years)		LVEF		Time since chemotherapy (months)	Treatment
Patient		Age (years)		LVEF		Time since chemotherapy (months)	Induction chemotherapy	Ablative chemotherapy	Radiotherapy, chest side/Gy
1	30	0.70	4	C	TMM	L/50
2	51	0.54	38	B	MM	R/50
3	40	0.52	48	C	TMM	L/70
4	51	0.53	66	B	TM	L/50
5	47	0.59	6	C	TMM	–/–
6	43	0.73	8	A	CTC	R/50
7	55	0.60	20	A	CTC	L/50
8	40	0.57	28	A	CTC	L/50
9	54	0.60	13	A	CTC	R/50
10	51	0.64	30	A	CTC	R/50
11	51	0.60	19	A	CTC	L/50
12	48	0.65	8	A	CTC	R/50
13	50	0.65	17	A	CTC	R/32
14	47	0.63	34	A	CTC	L/50
15	34	0.62	21	A	CTC	R/50
16	49	0.65	1	A	CTC	–/–
17	49	0.61	108	B	MM	–/–
18	39	0.61	54	B	TM	R/50
19	43	0.60	2	A	CTC	L/50
20	46	0.52	54	B	MT	L/50
Mean (SD)	45 (7)	0.59 (0.06)	29 (27)

A, chemotherapy regimen A; B, chemotherapy regimen B; C, chemotherapy regimen C; CTC, cyclophosphamide + thiotepa + carboplatin; L, left side of the chest; LVEF, left ventricular ejection fraction; MM, mitoxantrone + melphalan; R, right side of the chest; TM, thiotepa + mitoxantrone; TMM, thiotepa + mitoxantrone + melphalan.